PATENT CLAIM ANALYSIS

Application Number: 16529400
Application Type: Utility
Filing Date: 2019-08
Publication Date: 2019-11
Patent Classification: ["514", "401000"]

Abstract:
Disclosed is a single unit oral dosage form having, in combination, inositol and an extended release clonidine or extended release guanfacine. In one aspect, a method for treating ADHD and/or associated symptoms thereof includes administering to an ADHD patient the single unit oral dosage form. In another aspect, a method for treating ADHD and/or associated symptoms thereof includes administering to an ADHD patient inositol in combination with extended release clonidine or extended release guanfacine, whether administered separately or as a single dosage form.

Claim (Index 29):
The method of  claim 21 , the patient having the core symptoms of ASD, wherein the inositol is cumulatively provided in an amount of at least 12,000 mg per day and wherein the method treats the patient's core symptoms of ASD.

Metadata:
- Claim Count in Document: 47.0
- Percentile: 100.0
- Lexical Diversity: 2.11628
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['14245121', '13860824', '15346079', '13656415', '15102871']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7899974104417419
- 35 USC 102 Novelty (BERT): 0.5709453634864449
- Combined Prediction Score: 0.7680922057462122
- Mean Citation Score: 386.91969
- Max Citation Score: 559.2398
- Similarity Product: 331.7911982542396

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test